Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Chemo ± immunotherapy remains utilized for chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment patterns, and age disparities in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

JIJavier Pinilla IbarzSCSwetha ChallagullaQFQianhong Fu

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals treatment patterns and healthcare resource use in chronic lymphocytic lymphoma in the US, highlighting disparities in older populations.

Key Points

  • The aim was to assess treatment utilization patterns and healthcare resource use for chronic lymphocytic lymphoma among all patients and the elderly.
  • Retrospective study design using the USA Symphony Integrated Dataverse
  • Identified adults with chronic lymphocytic lymphoma who initiated treatment between 2022 and 2025
  • Categorized treatment regimens into four groups: chemo ± immunotherapy, anti-CD20-based therapies, BTKi, and BCL2i
  • Evaluated healthcare resource utilization during treatment
  • Included 37,341 patients with chronic lymphocytic lymphoma, with 20,729 initiating first-line therapy
  • Bruton tyrosine kinase inhibitors were the most commonly used regimen across treatment lines
  • The use of chemo ± immunotherapy and anti-CD20 regimens was retained in over 14% of first-line patients as of 2025
  • BTKi-treated patients had the lowest healthcare resource utilization compared to other regimens in all lines of therapy

Cite This Study

Ibarz et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db84https://doi.org/10.1182/blood-2025-2762
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States2025
  2. 2Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy2025
  3. 3Therapeutic utilization in chronic lymphocytic leukemia: A cross-sectional analysis of the Lymphoma Coalition’s 2022 Global Patient Survey.2024
  4. 4Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry2024 · 14 citations
  5. 5A decade of progress: A comparative analysis of real-world survival in chronic lymphocytic leukemia across therapeutic eras2025